Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration - a Swedish nationwide retrospective study

Lauppe, R; Nilsson, FOL; Wahl, HF; Lilja, M; Vikstrom, A; Asanin, ST

Lauppe, R (通讯作者),Quantify Res, Hantverkargatan 8, S-11221 Stockholm, Sweden.

ACTA ONCOLOGICA, 2022; 61 (11): 1354

Abstract

Background The real-world treatment and outcomes of patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer treat......

Full Text Link